News

E-Cadherin Levels Drive Entinostat Efficacy in NSCLC


 

The symposium was cosponsored by the American Society of Clinical Oncology, the American Society for Radiation Oncology, the International Association for the Study of Lung Cancer, and the University of Chicago.

Syndax Pharmaceuticals sponsored ENCORE 401. Dr. Jotte and his coauthors disclosed no conflicts of interest. Dr. Jänne disclosed financial relationships with AstraZeneca, Boehringer Ingelheim, Genentech, Pfizer, Roche, Gatekeeper Pharmaceuticals, and Genzyme.

Pages

Recommended Reading

FDA: Bevacizumab Should No Longer Be Indicated for Breast Cancer
MDedge Internal Medicine
ABCSG-12 Shows Benefit for Zoledronic Acid in Early Breast Cancer
MDedge Internal Medicine
Cancer Risk Doubled in Children with JIA
MDedge Internal Medicine
Rituximab Reduces Chronic GVHD After Allogeneic Stem Cell Transplant
MDedge Internal Medicine
Study Highlights Gaps from Inpatient to Outpatient Care
MDedge Internal Medicine
Horse Beats Rabbit in Antithymocyte Globulin Race
MDedge Internal Medicine
Subcutaneous Bortezomib in Myeloma Matches IV For Efficacy, Has Better Safety Profile
MDedge Internal Medicine
TDP Risk With Drug for Chemotherapy-Induced Nausea and Vomiting
MDedge Internal Medicine
Thrombosis Risk Rises in Women With Myeloproliferative Disorders
MDedge Internal Medicine
AMG 479 Fails to Alter Resistance to Endocrine Therapy for Breast Cancer
MDedge Internal Medicine